Banner - NPPA Connect
NP/PA Connect
News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
More
Publication
Dermatology Times
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • NP/PA Connect
  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Non-Melanoma Skin Cancers
  • Vitiligo
  • Wound Care
Advertisement

Edgar Charles, MD

Advertisement

Edgar Charles, MD, is vice president and senior global program lead of Early/Late Development Immunology at Bristol Myers Squibb.

Articles by Edgar Charles, MD

Edgar Charles, MD, on Long-term Deucravacitinib Psoriasis Data

ByMaddi Hebebrand, MC, Associate Editor,Edgar Charles, MD
March 3rd 2025
Advertisement

Latest Updated Articles

  • Edgar Charles, MD, on Long-term Deucravacitinib Psoriasis Data
    Edgar Charles, MD, on Long-term Deucravacitinib Psoriasis Data

    Published: March 3rd 2025 | Updated:



Advertisement
Advertisement

Trending on Dermatology Times

1

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

2

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older

3

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

4

Introducing Dermatology Times NP/PA Connect

5

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA

  • About
  • Advertise
  • Contact Us
  • Job Board
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy Policy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us